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Invariant natural killer T (NKT) cells might contribute to the amplified and prolonged T-cell
immune response that characterizes sarcoidosis. Therefore, we want to investigate the
frequency and distribution of pulmonary invariant NKT cells in corticosteroid-naı¨ve patients
with sarcoidosis. We used multi-parameter flow cytometry with antibodies against CD3, CD4,
CD8, CD14, CD19, CD45, CD16/56, TCR Va24, and TCR Vb11, on bronchoalveolar lavage fluid
(BALF), to examine the frequency and distribution of pulmonary invariant NKT cells in 47 newly
diagnosed sarcoidosis patients and in 8 control subjects. The frequencies of BALF Va24 Vb11
invariant NKT cells were significantly lower in patients with sarcoidosis in comparison to
control subjects. Moreover, lower invariant NKT cell frequencies in patients with sarcoidosis
significantly correlated with exaggerated BALF lymphocytosis and CD4 T cell responses. This
study demonstrated a pulmonary deficiency in the frequency of a subset of T cells with immu-
noregulatory function in patients with sarcoidosis.
ª 2009 Elsevier Ltd. All rights reserved.Introduction
Sarcoidosis is a multi-system disorder that predominantly
involves the lungs and is characterized by a Th1-biased,
CD4-positive T cell response and granuloma formation.1
Despite progress in the characterization of the immune
profile, little is known about the aetiology of sarcoidosis
and how its response is generated. Recently, newly2569 432; fax: þ386 4 2569
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9 Elsevier Ltd. All rights reservedidentified subsets of T cells with immunoregulatory func-
tions, invariant natural killer T (invariant NKT) cells, have
shown to be deficient in the peripheral blood of sarcoidosis
patients.2 NKT cells comprise a unique subgroup of
lymphocytes that express features of both T and natural
killer (NK) cells. These cells co-express T cell receptors
(TCR) as well as markers associated with NK cells, such as
CD56 and/or CD161.3 In humans, two major subsets of
natural killer T cells have been described.4 The more widely
studied subset is invariant NKT cells, which express a highly
restricted T cell receptor with an invariant Va24-Ja18 chain
paired with Vb11 and are dependent on the presentation of
the glycolipid antigen through CD1d, a member of class I.
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second class of NKT cells, CD1d- independent cells, express
a non-biased TCRa/b repertoire and are independent of
CD1d for their activity.6,7 Upon activation, NKT cells rapidly
produce both Th1- and Th2-specific cytokines, notably IL-4
and IFN-g, and exhibit both antigen-specific and NK-like
cytolytic activities.4,6 Their cytokine secretion is deter-
mined by the integration of different signals received in the
periphery.8 This rapid cytokine production is a manifesta-
tion of innate-like immunity and provides NKT cells with the
ability to link the innate and adaptive immune responses.
The dual regulatory and adjuvant functions of NKT cells are
still poorly understood. Invariant NKT cells might partici-
pate in the innate immune response to promote antimi-
crobial9 and anti-tumor immunity.10,11 Second, they can
actively induce T cell tolerance12 and protect against
autoimmune disorders with increased CD4-positive Th1
responses in preclinical models of type 1 diabetes,13,14
multiple sclerosis,15,16 and rheumatoid arthritis.17 Since,
invariant NKT cells were also implicated in the regulation of
Th1-based response and deficiency of invariant NKT cells
was found in the peripheral blood of sarcoidosis patients,
but inadequately evaluated in the lung,1 we examined the
frequency and distribution of pulmonary invariant NKT cells
in the bronchoalveolar lavage fluid (BALF) of large number
of corticosteroid-naı¨ve sarcoidosis patients.
Materials and methods
Patients
Forty-seven patients (mean ageZ 47 years; range 26e72
years; 24 women and 23 men; 5 smokers and 13 ex-smokers,
Caucasians) were recruited from the University Clinic of
Respiratory and Allergic Diseases in a prospective way over
a 2.5-year period. All patients were subjected to a diag-
nostic work-up, which included posteroanterior chest
radiography, optionally high-resolution CT, pulmonary
function tests, and fiberoptic bronchoscopy with biopsy and
bronchoalveolar lavage (BAL) (Table 1). All patients had
newly diagnosed, histologically confirmed pulmonary
sarcoidosis, without previous corticosteroid treatment. TheTable 1 Bronchoalveolar lavage fluid (BALF) cell counts
and results of lung function testing from control subjects
and study patients with sarcoidosis. Data are presented as
median with range in parentheses.
BALF cell counts: Controls
(NZ 8)
Sarcoidosis
(NZ 47)
Total cells (105cells/ml) 0.95 (0.6e5.3) 1.3 (0.3e4.2)
Neutrophils (%) 2 (1e7) 3 (1e40)
Eosinophils (%) 1 (1e2) 1 (1e5)
Macrophages (%) 90.5 (82e95)* 55 (14e96)
Lymphocytes (%) 6 (2e14)* 33 (3e77)
Lung function: FEV1 (%) 99.5 (86e121)* 90.5 (22e136)
FVC (%) 98.5 (78e119) 90 (33e122)
DLCO (%) 90.5 (74e105) 86 (42e134)
* Significantly different from the values for patients with
sarcoidosis, P< 0.04; ManneWhitney test.diagnosis of sarcoidosis was in agreement with the state-
ment adopted by the joint committees of ATS and ERS.18
Lofgren’s syndrome, which was defined as acute presenta-
tion, with or without fever, with erythema nodosum and
polyarthralgia and bilateral hilar lymphadenopathy on
chest radiography, was identified in 14 of those patients.
Fifteen patients had Scadding chest X-ray stage 1 chest
radiograph, 28 stage 2, three stages 3 and one stage 4
radiograph at the time of diagnosis.19 All patients were
followed up for 1 year according whether treatment was
required and whether there was need for long-term treat-
ment. We also included 8 control subjects without any
pulmonary morbidities (mean ageZ 56 years; range 28e84
years; 5 women and 3 men; 1 smokers and 1 ex-smokers,
Caucasians). Both groups showed no significant differences
according to age, sex and smoking habit (t and Fischer’s
test). All subjects gave their written consent and the study
was approved by the National Ethics Committee.
Bronchoalveolar lavage procedure
Bronchoalveolar lavage (BAL) was performed as previously
described.7 Briefly, we instilled 7 aliquots of 20 ml and one of
10 ml, up to a total volume of 150 ml of saline. After each
instillation the aliquot was immediately recovered, pooled
and thereafter proceed for cytological and flow cytometry
analysis. Cytospinpreparationswere stainedaccording to the
May-Gru¨nwald Giemsa and Papanicolaou method. Differen-
tial cell counts were performed by one observer blinded to
the clinical characteristics, counting 200 cells (Table 1).
Flow cytometry
Flow cytometry was performed as previously described7 on
an FACSCalibur (BD Biosciences, San Jose, CA, USA) using
mAb against CD3, CD4, CD8, CD14, CD19, CD45, CD16/56,
Va24 (clone 6B11) T cell receptor (TCR) (all from BD
Biosciences), Vb11 TCR (Immunotech, Marseille, Fran-
ce),20e22 and isotype-matched antibody controls (BD
Biosciences) that were directly conjugated to either FITC,
PE or PerCP. The BALF was first strained through a 70 mm
cell strainer (BD Biosciences); the cells were centrifuged at
460 g for 5 min, resuspended in Haemaccel (Behring-
werke, Marburg, Germany), and incubated with the
respective mAbs for 15 min, followed by lysing, washing,
and fixation. Labeled cells were analyzed by CellQuest
software (BD Biosciences). Lymphocytes were distinguished
by the initial gating using characteristic lymphocyte
forward/side-scatter properties and the gate was further
confirmed by CD14/CD45 staining. Invariant NKT cells
(CD3þ Va24þ Vb11þ), NKT cells (CD3þ CD16/56þ), natural
killer (NK) cells (CD3-CD16/56þ), helper and suppressor T
cells, and B lymphocytes were scored in percentages of
lymphocytes.
Statistical analyses
The distribution of data was tested by the ShapiroeWilks
test. Since the data were not normally distributed, we
performed a ManneWhitney. The strength of association
between invariant natural killer T cells and other variables
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bility values of P< 0.05 were accepted as significant.
Analyses were performed with GraphPad Prism 5.
Results
When specimens of BALF were examined for the presence
of CD4þ and CD8þ T cells, we observed a higher number of
CD4þ cells, with an increase in the CD4:CD8 ratio in
patients with sarcoidosis and a lower number of CD4þ cells
with a normal CD4:CD8 ratio in control subjects (Table 2).
In all study subjects, the majority of pulmonary
lymphocytes were T cells, with a very low number of B
lymphocytes, thus the frequencies of T cells and the
lymphocyte counts were higher in sarcoidosis patients
(Tables 1 and 2). The sarcoidosis group further showed
lower macrophage counts (Table 1). There was no signifi-
cant difference in the presence of BALF natural killer cells
and natural killer T cells, as detected by staining with
monoclonal antibodies to CD3 and CD16/56 (Table 2).
We then examined the BALF for the presence of
invariant NKT cells, as detected by staining with mono-
clonal antibodies to CD3, Va24 and Vb11 T cell receptors.
We found a striking reduction in pulmonary lymphocytes co-
expressing invariant T cell receptors in patients with
sarcoidosis (Figs. 1 and 2). The median (range) percentage
of lymphocytes staining for CD3, Va24 and Vb11 TCR
was 0.19% (0.001e2.9%) for patients with sarcoidosis. This
was significantly lower than in control subjects. (1.03%
(0.13e1.4%); PZ 0.001; ManneWhitney test).
We also analyzed the frequencies of BALF invariant NKT
cells in different clinical categories of our patients, divided
according to the mode of presentation (Lofgren’s syndrome
vs. other forms), and in patients with different chest
radiograph stages. Invariant NKT cell frequencies were
comparably low in both clinical categories of sarcoidosis
patients (median (range); Lofgren’s syndrome vs. other
forms; 0.21% (0.02e1.1%) vs. 0.19% (0.001e2.9%)) and in
different radiograph stages (median (range); without vs.
with parenchymal disease 0.15% (0.001e1.1%) vs. 0.23%
(0.02e2.9%)). There was also no difference according to
smoking history (smokers and ex-smokers vs. non smokers;
0.21% (0.001e1.9%) vs. 0.19% (0.02e2.9%)) or sex.Table 2 T lymphocytes, B lymphocytes, NK and NKT cells
in BALF from study subjects. Data are presented as median
with range in parentheses.
% of lymphocytes Controls
(NZ 8)
Sarcoidosis
(NZ 47)
T lymphocytes (CD3þ) 85 (76e97)* 92 (74e100)
T helper (CD3þ CD4þ) 55 (38e80)* 77 (15e92)
T suppressor (CD3þ CD8þ) 24.3 (13e52)* 13 (2e84)
B lymphocytes (CD19þ) 0 (0e4) 1 (0e4)
NK cells (CD3-CD16/56þ) 3 (2e7) 2 (1e13)
NKT cells (CD3þ CD16/56þ) 3 (2e5) 2 (0e11)
CD4/CD8 ratio 2.3 (0.8e6.2)* 6.3 (0.2e46)
*Significantly different from the values for patients with
sarcoidosis, P< 0.03; ManneWhitney test.Eighteen of 33 patients with non-Lofgren’s sarcoidosis
were treated with systemic steroid therapy. In those
patients, we found slightly lower pre-treated frequencies
of invariant NKT cells than in patients without need for
corticosteroid treatment (0.11% (0.02e1.3%) vs. 0.31%
(0.001e2.9%)). However, these differences did not reach
statistical significance. Eleven patients needed only one
period of treatment, lasting for a maximum of 1 year, but 7
patients needed treatment with corticosteroids for more
than 1 period or long-term treatment lasting for more than
1 year. Both subgroups showed comparable pre-treated
frequencies of BALF invariant NKT cells.
Because a major fraction of pulmonary T cells in patients
with sarcoidosis were CD4þ T cells, we wanted to establish
whether there was any correlation between frequencies of
BALF invariant NKT cells and the predominance of CD4þ T
cells in the sarcoidosis group. First, we found a significant
negative correlation between BALF invariant NKT cells
frequencies and the total cell count (PZ 0.001,
RZ0.48), lymphocyte count (PZ 0.01, RZ0.37), and
the concentration of BALF lymphocytes (P< 0.0001,
RZ0.58; Spearman method) in the sarcoidosis group.
Second, there was a significant negative correlation
between invariant NKT cell frequencies and BALF concen-
tration of T cells (P< 0.0001, RZ0.58) and CD4þ T cells
(PZ 0.0008, RZ0.47; Spearman method). There was
also a significant correlation with macrophage counts
(PZ 0.003, RZ 0.43). However, there was no significant
correlation between the invariant NKT cells and other BALF
cells, other T, B or NK lymphocyte subgroups, pulmonary
function test results or age in patients with sarcoidosis.
Moreover, we could not demonstrate any significant corre-
lation between BALF invariant NKT cells and any variables
in the control group, such as BALF cell counts, T, B, or NK
lymphocytes, pulmonary function test results or age.
The BALF invariant NKT cells frequencies were also
evaluated by ROC curve analyzes (Fig. 3). The area under
a ROC curve was 0.79 and the P value was 0.009. The
optimal recalculated threshold was <0.97%, with the
sensitivity of 87% and the specificity of 75%. ROC curve
analyzes were also performed for CD4:CD8 ratio (Fig. 3).
The optimal CD4:CD8 threshold was >3.3, with the sensi-
tivity of 70% and the specificity of 88%, and with area of
0.79 and the P value of 0.01.Discussion
In this work, we evaluated the frequencies of invariant
Va24 Vb11 NKT cells in the bronchoalveolar lavage fluid of
sarcoidosis patients. Previous report of Ho et al.2 demon-
strated the peripheral blood deficiency of invariant NKT
cells in sarcoidosis patients. However, previous data were
not consistent at the pulmonary or granuloma level. Mem-
pel et al.23 have reported an absence of invariant NKT cells
in cutaneous lesions of sarcoidosis patients. In contrast,
Kobayashi et al.24 suggested accumulation of invariant NKT
cells in granulomatous lesions. Ho et al.2 also demonstrated
low numbers of invariant NKT cells in BALF of sarcoidosis
patients, but BALF were done only in limited number of
patients and with no data in control subjects. Thus
sarcoidosis is a multi-system disorder that predominantly
Figure 1 Flow-cytometric analysis of invariant NKT (CD3þ Va24þ Vb11þ) in bronchoalveolar lavage fluid from two patients with
Lofgren’s syndrome (panel A), a patient with non-Lofgren sarcoidosis (panel B), and two control subjects (panel C). Cells were
stained with mAbs against CD3, Va24þ and Vb11þ TCR. Dot plots were generated after first forward/side-scatter lymphocyte
gating and second CD3þ gating.
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Figure 2 Summary plot of invariant NKT (CD3þ Va24þ
Vb11þ) cell frequencies in BALF of patients with sarcoidosis
and control subjects. The horizontal solid bars indicate the
median value for each group.
574 P. Korosec et al.involves the lungs, and therefore, we focused on the BALF
pulmonary T cells. We demonstrated a major pulmonary
deficiency of Va24 Vb11 invariant NKT cells in the lungs
airway lumen of newly identified, corticosteroid-naı¨ve
sarcoidosis patients with approximate 5 fold reduction in
comparison to control subjects. Moreover, invariant NKT
cell frequencies were in significant negative correlation
with the BALF lymphocytosis and with the amplified BALF T
cell and CD4þ T cell response.
Several recent studies were undertaken with the aim of
clarifying the aetiopathology of sarcoidosis. These studies
provided evidence that patients with sarcoidosis have an
exaggerated Th1-biased, CD4-positive T cell response which
might includes different subsets of CD4 T cells from CD4 T
cells lacking CD2825 to AV2S3þ CD4 T cells.26 They
hypothesized that formation of organized immune granu-
lomas might be a response to undefined antigen; however,
what causes cells of the immune system to behave in this
amplified manner is unknown. Ho et al. recently suggested
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Figure 3 ROC curve analysis of BALF invariant NKT cells and CD4:CD8 ratio. The area under a ROC curve for was 0.79 and the
P value was 0.01. The optimal threshold was <0.97% for invariant NKT cells was and >3.3 for CD4:CD8 ratio.
Invariant NKT cells in sarcoidosis 575that loss of an immunoregulatory subset of T cells, like
invariant NKT cells, could contribute to the lack of control
of CD4-positive T cells.2 This idea is supported by studies
with animal models, which has shown that invariant NKT
cells protect against disorders with increased CD4-positive
Th1 responses.13e17 The most persistent data are in the
nonobese diabetic (NOD) mouse strain that spontaneously
develops autoimmune diabetes and exhibits both quanti-
tative and qualitative invariant NKT cell defects.13,14 This
idea was further supported by the findings that reconsti-
tution of invariant NKT cells prevented chronic immune
damage to the pancreatic islet cells and the development
of diabetes.13,14 Furthermore, there is evidence that indi-
viduals predisposed to diabetes mellitus have dysfunction
of invariant NKT cells.27
The possible deficiency of invariant NKT cells in
sarcoidosis patients opens several important clinical ques-
tions. First, is there any correlation between invariant NKT
cells and the clinical course and/or therapeutic conse-
quences of sarcoidosis? It is well-described that patients
with Lofgren’s syndrome have a better prognosis than do
patients with other manifestations of the disease.28 More-
over, Lofgren’s syndrome is characterized by a defined start
and end of immune activity, as more than 80% of patients
have complete disease resolution within 1e2 years.
Consequently, only 1 (7%) of our Lofgren patients had
required corticosteroid treatment. By contrast, patients
who present with classical pulmonary infiltrates tend to
have a longer clinical course, and indeed, 18 (53%) our non-
Lofgren patients required corticosteroid treatment. We
demonstrated that the frequencies of invariant NKT cells
were comparably low in both phenotypes in different
radiograph stages at the starts of the disease. All patients
were clinically followed up to 1 year after the inclusion into
the study, and the patients who required corticosteroid
treatment tended to have lower initial frequencies of
invariant NKT cells. However, those differences did not
reach statistical significance, and pre-treated deficiency
was comparable between patients who needed only one
period of treatment, lasting for at most 1 year, and patients
who needed treatment with corticosteroid for more than 1
period or long-term treatment lasting for more than 1 year.
The major question that remains unanswered is what
happens to invariant NKT cells during the course of the
disease and do those cells influence the course of disease
by limiting the expansion of antigen-driven T cells.Unfortunately, none of the current studies follows up
invariant NKT cells through the course of disease, and these
observations are only a single time point of the disease
process.
It is noteworthy that sarcoidosis patients do not share
pulmonary invariant NKT abnormalities with other intersti-
tial lung diseases, like hypersensitive pneumonitis, or with
puzzling observations in obstructive lung diseases. A ROC
curve analyse even suggests that evaluation of BALF
invariant NKT cell frequencies might be helpful in the
differential diagnosis. We have recently shown significantly
increased levels of BALF CD8þ CD56þ NKT cells that did not
express the invariant T cell receptor in hypersensitive
pneumonitis, but no such differences were observed in
sarcoidosis patients.7 We confirmed these recent observa-
tions also in this study, as both sarcoidosis and control
subjects have normal BALF CD56þ NKT numbers. Similar
data were observed in two other previous reports.29,30
Despite initial identification of NKT cells by invariant TCRa
chain and NK surface antigens, CD56 and/or CD161, it is
now evident that NKT cells comprise a heterogeneous
subgroup with functionally distinct subpopulations that
express different patterns of a/b T cell receptors and NK
cell antigens.3e7
Much more controversial are data about invariant NKT
cells in asthma. Akbari et al.20 demonstrated highly
increased number of invariant NKT cells (about 60% of CD3þ
CD4þ cells) in the lungs of patients with asthma, and
a requirement for invariant natural killer T cells was indi-
cated in the development of allergen-induced airway
hyperreactivity in mice.31 These findings have been chal-
lenged by Vijayanand et al.21 and Thomas et al.,22 who
showed significantly lower invariant NKT cells counts in
asthma (fewer than 2% of T cells). Thomas suggested that
this discrepancy may result from different gating strate-
gies, as in BALF, it is very important to gate using charac-
teristic lymphocyte forward-scatter (size) and side-scatter
(granularity) to exclude large granular cells that might stain
nonspecifically. Nevertheless, the critical question is what
the ‘‘normal’’ frequency of BALF invariant NKT cells is. For
example Akbari et al.20 and Mutalithas et al.32 included
sarcoidosis patients as a control subjects, and these was
also the case for recent communication of Akbari group.33
On the other hand Vijayanand21 and Thomas22 did not
include any control BALF samples. However, both Vijaya-
nand and Thomas, which used methodologically
576 P. Korosec et al.comparably setting as in our report, showed comparable
BALF invariant NKT asthma count as our values in control
subject.
The deficiency of invariant NKT cells in sarcoidosis
patients is unexplained. The possible cause might include
an absence or reduction due to genetic predisposition;
cellular relocation might not be the case, as deficiency was
observed in different compartments. Baev et al.34 recently
characterize one of the mechanisms that drive NKT cell
differentiation and demonstrate that this mechanism is
impaired in NOD mice that lack regulatory invariant NKT
cell function. NOD mice carry a genetic defect of the
Slamf1 gene that is associated with reduced signaling
lymphocyte activation molecule (SLAM) expression on
double-positive thymocytes and altered invariant NKT cell
development in the thymus.34,35 Second, a recent study by
Cantorna et al.36 on a KO mice model showed that
expression of vitamin D receptor is required for normal
development and function of invariant NKT cells. Appar-
ently, the active form of vitamin D is produced at the sites
of the granulomatous reaction, and it was suggested that
vitamin D receptor gene polymorphism might be also
a genetic risk factor for sarcoidosis.37
In summary, this study demonstrated a pulmonary
defect in the frequency of a subset of T cells with immu-
noregulatory function in patients with sarcoidosis. More-
over, lower invariant NKT cell frequencies in BALF of
patients with sarcoidosis significantly correlated to
elevated BALF lymphocytosis and T and CD4 T cell expan-
sion. Therefore, our data suggest that this deficiency might
contribute to the amplified immune response.
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